[English]  [Pусский]  [中文]  
ctt-journal > Burkhardt (Abstract)

Burkhardt (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract69

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment


The current role of stem cell transplantation in children and adolescents with non-Hodgkin lymphoma

Birgit Burkhardt

NHL-BFM study Center and Clinic of Pediatric Hematology and Oncology, Muenster, Germany

Correspondence: Birgit Burkhardt, Universitätskinderklinik Münster Pädiatrische Hämatologie und Onkologie Albert-Schweitzer-Str. 33, D-48149 Münster, Germany, E-mail: Birgit.Burkhardt@spam is badpaediat.med.uni-giessen.de


Stem cell transplantation (SCT) is not part of current frontline treatment strategies for children and adolescents with non-Hodgkin lymphoma (NHL). Recommending treatment approaches for relapsed NHL pts continues to be a challenge.

Relapses of LBL occur very early and more than half of pts do not reach a second remission and die before planned SCT. The only surviving pts receive consolidation with allogeneic SCT after obtaining a stable remission.

Survival of pts with relapse of a mature B-NHL differs according to subtype. Without SCT pts have almost no chance to survive. Pts with DLBCL-relapse have a chance of >50% to reach a CCR by an autologous SCT. For Burkitt’s lymphoma-relapse pts the major goal is achieving a stable 2nd CR; relapses refractory to chemotherapy are not curable currently. Available data do not allow recommending the type of SCT for consolidation in Burkitt’s lymphoma relapse pts. The scarce data on PMLBL-relapses suggest that consolidation by allo SCT may be more promising than by auto SCT.

Pts with a relapse of an ALCL are the largest group of relapse pts, thus allowing risk stratification in relapse. About 20% of relapses are progression during front-line therapy. Survival of those pts has only been reported after allo SCT (OS 30–40%). Pts relapsing after frontline therapy have a chance to survive by different strategies including vinblastine-maintenance, auto, or allo SCT.
Conclusion: SCT has no relevant role in frontline treatment for childhood and adolescent NHL. In LBL and B-NHL-relapse pts, it is most crucial — and challenging — to reach a stable second CR before any type of SCT for consolidation. Recommendations for SCT type can currently be based on disease-entity and time of relapse/progression.

Keywords: Non-Hodgkin's Lymphoma, pediatric, stem cell transplantation, relapse